Clinical Trials Logo

Kidney Diseases clinical trials

View clinical trials related to Kidney Diseases.

Filter by:

NCT ID: NCT05851417 Recruiting - Kidney Diseases Clinical Trials

Fast Field Cycling Imaging of Kidney Disease

Start date: March 8, 2023
Phase: N/A
Study type: Interventional

The goal of this pilot study is to explore the utility of Fast Field-Cycling (FFC) imaging in monitoring kidney disease. The main questions it aims to answer are: - If FFC imaging can differentiate healthy kidney from kidney disease - If there is an association between FFC imaging and standard clinical tests Participants will provide one blood and on urine sample, and will have one FFC imaging scan.

NCT ID: NCT05846113 Active, not recruiting - Kidney Diseases Clinical Trials

Renasight Clinical Application, Review and Evaluation (RenaCARE) Study

RenaCARE
Start date: June 7, 2021
Phase: N/A
Study type: Interventional

This study is an open-label, multi-center study evaluating the clinical utility of Renasight in the diagnosis and management of kidney disease.

NCT ID: NCT05790109 Terminated - Liver Diseases Clinical Trials

Operator and Patient Acceptance of Radiofrequency Cautery of the Biopsy Track During Percutaneous Liver, Kidney or Spleen Biopsy Procedures.

Start date: May 23, 2023
Phase: N/A
Study type: Interventional

The goal of this study is to assess the physician and patient experience of radio frequency (RF) track cautery in patients undergoing needle biopsy of the liver, kidney, or spleen who have one or more risk factors for biopsy-related bleeding. RF track cautery involves inserting a bipolar electrode through the same introducer needle used for the biopsy, and heating the tissues along the path of the biopsy needle to prevent bleeding. This study primarily aims to assess the operator and patient experience during the use of track cautery. Secondary aims are to assess the technical success rate and procedure adverse events. Participants who enroll in the study will undergo track cautery as part of their clinically indicated liver, kidney, or spleen biopsy. After the procedure, they will fill out a brief survey asking about their experience during the procedure. Physician operators who perform track cautery as part of the study will also fill out a survey after each procedure asking about their experience using this technique.

NCT ID: NCT05784389 Recruiting - Kidney Diseases Clinical Trials

Reduction of Metabolic Acidosis in Patients With Chronic Kidney Disease in Stage 4 and 5

REMA-CKD
Start date: March 27, 2023
Phase: N/A
Study type: Interventional

This clinical trial aims to investigate and test the effect of an acid/base diet in chronic kidney disease (CKD) patients, CKD stage 4 and 5. The trial is guided by the hypothesis that an acid/base diet will reduce the degree of acidosis and simultaneously reduce the need for bicarbonate supplements.

NCT ID: NCT05777174 Recruiting - Kidney Diseases Clinical Trials

Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring

Start date: March 20, 2023
Phase: Phase 3
Study type: Interventional

The objective of this study is to establish that the MB-102 transdermal fluorescence-measured Glomerular Filtration Rate (GFR) using the MediBeacon® Measurement System with the Transdermal Glomerular Filtration Rate (TGFR) reusable sensor with disposable adhesive ring is comparable to the plasma-measured MB-102 GFR in normal and compromised renal function participants with different skin color types.

NCT ID: NCT05774392 Not yet recruiting - Clinical trials for End Stage Kidney Disease

An Observational Study of Patients With Chronic Kidney Disease

Start date: May 2023
Phase:
Study type: Observational

TARGET-KIDNEY is an observational research study to conduct a comprehensive review of outcomes for patients with chronic kidney disease (CKD) and end-stage renal disease (ESKD).

NCT ID: NCT05759754 Recruiting - Kidney Diseases Clinical Trials

Effects of Traditional Chinese Medicine (GSJYF) in Children With Inherited Proteinuric Kidney Disease

Start date: September 17, 2023
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether traditional Chinese medicine, Gu Shen Juan Yu Formula, as complementary treatment is safe and effective in the treatment of Inherited Proteinuric Kidney Disease.

NCT ID: NCT05747053 Terminated - Kidney Diseases Clinical Trials

Personalization of Immunosuppressive Treatment for Organ Transplant Recipients

STAART
Start date: October 1, 2020
Phase:
Study type: Observational

Long-term graft failure rates continue to be unacceptably high despite the development of immunosuppressive drugs, underscoring the unmet need for robust prognostic biomarkers of allograft injury and failure. While rates of acute rejection (AR) continue to decrease, it remains the strongest predictor of long-term allograft survival, and so having a better understanding of factors predicting AR may contribute to more individualized patient care. Selecting optimum immunosuppressive dosage is another factor in personalizing kidney care. This project will study two areas of individualized kidney care: 1) assessing rejection by surveillance testing utilizing AlloSure, 2) developing an algorithm to select optimum immunosuppressive medication dosage.

NCT ID: NCT05740709 Recruiting - Acute Kidney Injury Clinical Trials

Identification of Patients at Risk of CKD After AKI

Start date: March 1, 2023
Phase:
Study type: Observational

The investigators will investigate whether new kidney biomarkers can identify patients who are at risk of chronic kidney disease after an episode of moderate / severe acute kidney injury in ICU.

NCT ID: NCT05719714 Recruiting - Heart Failure Clinical Trials

Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease

Start date: January 16, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The goal of this study is to better understand the effects of a sodium-glucose transport protein 2 inhibitor, dapagliflozin, added on to standard of care on heart and lung function and circulating metabolites (substances created when our bodies break down food, drugs, or its own tissues) in patients with chronic kidney disease.